Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydroxytoluic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 1/20 | 0.43 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.42 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.42 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxytoluic Acid SCHEMBL1333592 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL4389834 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29975592 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL9418192 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL622891 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL31175008 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29380596 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29975309 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL29975360 | 0.96 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| Hydroxytoluic Acid SCHEMBL8929635 | 0.91 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041216-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2025-02-06 | — | — | US | claimed |
| US-11969503-B2 | Methotrexate composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2024-04-30 | — | — | US | claimed |
| CN-117065037-A | Pharmaceutical compositions comprising S1P modulators | 诺华股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-20230251277-A1 | METHOD FOR DETERMINING THE LEVEL OF VITAMIN D AND METABOLITES THEREOF | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-08-10 | — | — | US | claimed |
| EP-4222502-A1 | A METHOD FOR DETERMINING THE LEVEL OF VITAMIN D AND METABOLITES THEREOF | F. Hoffmann-La Roche AG (CH) | 2023-08-09 | — | — | EP | claimed |
| US-20230233464-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2023-07-27 | — | — | US | claimed |
| CN-116209901-A | Method for determining the amount of vitamin D and its metabolites | 豪夫迈·罗氏有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-114948868-B | Crystal form of lamotrigine hydrate, preparation method thereof and composition containing crystal form | 上海奥科达医药科技股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113679958-B | Equivalent tissue compensator and preparation method thereof | 无锡恒成医疗科技股份有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-115778897-A | Stable methotrexate pharmaceutical preparation and preparation method thereof | 深圳市贝美药业有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-1256706-A | Non-drying adhesive composition for treating surfaces | HENKEL ECOLAB GMBH & CO OHG (DE) | 2000-06-14 | — | — | CN | claimed |
| EP-0793495-B1 | FREEZE-DRIED ONDANSETRON COMPOSITIONS | GLAXO WELLCOME INC (CA) | 2000-05-31 | — | — | EP | claimed |
| US-6066629-A | DRY POWDER; MIXTURE CONTAINING LACTAMASE INHIBITOR | FUISZ TECHNOLOGIES LTD. (US) | 2000-05-23 | — | — | US | claimed |
| US-6063802-A | Ondansetron freeze-dried dosage form compositions for oral administration | GLAXCO WELLCOME INC. (CA) | 2000-05-16 | — | — | US | claimed |
| CN-1228959-A | Breviscapine soft capsule and its production method | KUNMING PHARMACEUTICAL CO LTD (CN) | 1999-09-22 | — | — | CN | claimed |
| US-5955488-A | ANTAGONIST OF 5-HYDROXYTRYPTAMINE FOR TREATMENT OF EMESIS | GLAXO WELLCOME INC. (CA) | 1999-09-21 | — | — | US | claimed |
| CN-1225581-A | Use of alpha blockers, in particular of thymol amine and/or its derivatives for the treatment of penile erectile dysfunction by the transmucosal glans route | BIOTEC CENTRE SA (FR) | 1999-08-11 | — | — | CN | claimed |
| EP-0793495-A1 | FREEZE-DRIED ONDANSETRON COMPOSITIONS | GLAXO WELLCOME INC. (CA) | 1997-09-10 | — | — | EP | claimed |
| WO-1996015785-A1 | FREEZE-DRIED ONDANSETRON COMPOSITIONS | GLAXO WELLCOME INC. (CA) | 1996-05-30 | — | — | WO | claimed |
| EP-0515758-B1 | Therapeutic use of 1,3-dimethylol-5,5-dimethyl hydantoin | ANBEN (FR) | 1995-03-22 | — | — | EP | claimed |